OMP-336B11
- Generic Name
- OMP-336B11
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
Phase 1
Terminated
- Conditions
- Locally Advanced Malignant NeoplasmMetastatic Cancer
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- OncoMed Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03295942
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath